Technology | June 28, 2006

Minimally Invasive Laser Solution for Atrial Fibrillation

A 1064 nm wavelength laser technology, the Atrilaze Surgical Ablation system complements its existing 810 nm technology.
The system is indicated for delivery of laser light to soft tissue, including cardiac tissue, during surgical procedures. Indications include the incision, excision, dissection, vaporization, ablation or coagulation of soft tissue.
Because it can be delivered through a 600 micron optical fiber, the Atrilaze system is designed for very small incisions, potentially enabling a stand-alone (closed-chest, beating heart) procedure.

Related Content

News
Medtronic Receives FDA Approval of Mapping and Ablation System and Catheter

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
News
BSC Launches Next Gen of Cardiac Mapping for Pulsed Field Ablation System

Oct. 18, 2024 — Boston Scientific Corp. recently announced it has received U.S. Food and Drug Administration (FDA) ...

Home October 21, 2024
Home
CardioFocus will feature its portfolio of innovative ablation systems which optimize lesion creation via confirmed tissue contact and sophisticated energy delivery
News
CardioFocus to Present Data Supporting Next Generation Pulsed Field Ablation Systems at Heart Rhythm 2024

May 15, 2024 —CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
Innovative Health, Inc. has announced that recent growth in single-use device reprocessing has delivered significant financial and environmental benefits to U.S. electrophysiology labs, and will be participating in the Heart Rhythm Society annual meeting, HRS 2024, May 16-19 in Boston, MA.
News
Innovative Health to Report Strong Growth in Cost and Environmental Savings for EP Labs at the 2024 Heart Rhythm Society Conference

May 13, 2024 — Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months
News
Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems
News
Boston Scientific Receives FDA Approval for the POLARx Cryoablation System

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.
News
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
The Arrhythmia Care Team at Corewell Health Celebrate First Successful Procedures With New Genesis Robotic Cardiac Ablation System from Stereotaxis.
News
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated announced submission of pivotal clinical data from the AcQForce Flutter trial
News
Acutus Medical Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter and System

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally
News
Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now